Orphan Drugs Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017–2023 Overview: Orphan diseases or rare diseases rarely occur among the people, which is nearly 7 out of 10,000 individuals. Around 5,000 to 8,000 rare diseases have been recognized and the origin of approximately 80% of these diseases is from the genes. Regardless of the alleged huge number of individu

Published by Infoholic Research on 6th September 2017 | Ref: 842453 | This Report Is In Stock

$2500 | Single User
$2750 | Site License
$3000 | Enterprise License
$2500 | Single User
$2750 | Site License
$3000 | Enterprise License

Introduction

Orphan Drugs Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017–2023

Overview: Orphan diseases or rare diseases rarely occur among the people, which is nearly 7 out of 10,000 individuals. Around 5,000 to 8,000 rare diseases have been recognized and the origin of approximately 80% of these diseases is from the genes. Regardless of the alleged huge number of individuals being affected by rare life-threatening conditions, the disease burden estimates of the public health are unreliable. About 50% of the orphan genetic ailments are in kids’ with 30% of them cannot live for more than 5 years.

New-born screening, legislation, and construction of national strategies are the major activities being carried out in the orphan drugs market. Legislation has helped in driving the development of more orphan drugs. For instance, the US congress passed Orphan Drug Act in 1983, and it was mainly intended to encourage development of new drugs for rare diseases. Currently, numerous legislation and strategies are developed to facilitate research of orphan drugs globally in more than 35 countries.

Cancer, metabolic diseases, blood diseases, immunologic disease, and neurologic diseases are the types of diseases that are addressed with orphan drugs. Cystic fibrosis, glioma, pancreatic cancer, acute myeloid leukemia, multiple myeloma, renal cell carcinoma, ovarian cancer and Duchenne muscular dystrophy are some of the common indications among the various disease types.

Market Analysis: The “Global Orphan Drugs Market” is estimated to witness a CAGR of 11.9% during the forecast period 2017–2023. The market is analyzed based on three segments, namely types, applications, and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is the leading region for the orphan drugs market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions. India, China, and Japan are set to be the most attractive destinations due to the large untapped market.

Types Analysis: The global orphan drugs market by products is segmented into biologics and non-biologics. Biologics orphan drugs is the largest segment in the market with a market share of more than 60% in 2016. It is expected to grow at a double-digit CAGR in the market. However, non-biologic orphan drugs are still expected to hold more than quarter of the market share by 2023. The market is also witnessing various mergers, acquisitions, and collaborations among the top players, which is defining the future of the global orphan drugs market.

Key Players: Novartis AG, F. Hoffmann-La Roche Ltd, Celgene, Bristol-Myers Squibb Company, Shire pharmaceuticals, Pfizer, Sonafi, and Bayer Healthcare are the key players in the market. These top ten players occupy nearly 50% of the orphan drugs market.

Competitive Analysis: Currently, large pharmaceutical companies are extremely active in the orphan drugs market. Merger and acquisition is the major trend in the market. For instance, around 40% of the biotechnology companies are acquired between the year 2008-2012, and they have an orphan drug in development. Novartis, GSK, Roche, and Pfizer are the largest orphan drug companies. Pfizer, Gilead, Roche, Shire, BMY, and Celgene are leading orphan drug acquirers. Around 50% of the top 20 orphan drugs were either acquired or in-licensed by large pharmaceutical companies.

Benefits: The report provides complete details about the usage and adoption rate of orphan drugs during the forecast period and among the regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives toward the orphan drugs adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

Table of Contents

Table of Contents

1 Industry Outlook 10

1.1 Industry Overview 10

1.2 Industry Trends 10

2 Report Outline 12

2.1 Report Scope 12

2.2 Report Summary 12

2.3 Research Methodology 13

2.4 Report Assumptions 13

3 Market Snapshot 15

3.1 Market Definition – Infoholic Research 15

3.2 Segmented Addressable Market (SAM) 15

3.3 Related Addressable Markets (RAM) 17

4 Market Outlook 20

4.1 Overview 20

4.2 Regulatory Framework for orphan drugs 20

4.3 Funding Scenario for orphan drugs 22

4.4 Market Segmentation 23

4.5 Porter 5(Five) Forces 24

4.6 PEST Analysis 25

5 Market Characteristics 26

5.1 Market Dynamics 26

6 Drug Details: Market Size and Analysis 30

6.1 Overview 30

7 Types: Market Size and Analysis 46

7.1 Overview 46

8 Application: Market Size and Analysis 50

8.1 Overview 50

9 Pipeline Molecules: Market Size and Analysis 55

9.1 Overview 55

10 Regions: Market Size and Analysis 71

10.1 Overview 71

10.2 North America 72

10.3 Europe 74

10.4 APAC 75

10.5 Rest of the World 79

11 Competitive Landscape 81

12 Vendor Profiles 83

12.1 Novartis AG 83

12.2 F.Hoffmann-La Roche Ltd 90

12.3 Celgene Corporation 97

12.4 Bristol-Myers Squibb 101

12.5 Shire PLC 107

13 Companies to Watch For 114

13.1 Pfizer Inc., 114

13.2 Sanofi 116

13.3 Bayer AG 117

13.4 Alexion Pharmaceutical Inc. 118

13.5 Biogen Pharmaceuticals. 119

13.6 Eli Lilly and Company. 121

13.7 Amgen Inc. 122

Annexure 125

Abbreviations 125

Additional Details

Publisher

Infoholic Research

Publisher Information

Reference

842453 |

Number of Pages

125

Report Format

PDF

This report is published by Infoholic Research

Download Free Report Summary PDF

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.